...Wen Cai; Jiwei Huang; Yichu Yuan; Xiaoyi Hu; Mingyang Li; Wen Kong; Jin Zhang; Jianming Guo; Yonghui Chen; Yiran Huang Objectives: The purpose of this work was to investigate the effect of sorafenib or sunitinib as neoadjuvant therapy on the survival outcomes of renal cell carcinoma (RCC...

... endothelial growth factor (VEGF), have also been implicated. We report here the case of a 71-year-old woman with metastatic clear cell renal carcinoma who developed PRES 3 months after commencing sorafenib. Elevated blood pressure (BP) was recorded, and MRI of the brain) of the brain showed asymmetric areas...

...Masaomi Ikeda; Tetsuo Fujita; Yasuyuki Amoh; Sumiyuki Mii; Kazumasa Matsumoto; Masatsugu Iwamura Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent. Skin toxicity, such as hand-foot skin reaction, is one...

... a presurgical targeted therapy to downsize the thrombus and primary tumor, which may reduce the extent of the surgery and operative risk. The patient accepted this approach with administration of sorafenib, resulting in a marked reduction of the primary renal tumor and 43% regression in tumor thrombus. Tumor...

...Yao Zhu; Hui Li; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Guo-Hai Shi; Li-Feng Yang; Zhong-Yi Yang; Chao-Fu Wang; Ding-Wei Ye Introduction: We describe our experience with sorafenib and sunitinib in the treatment of chemotherapy-refractory advanced penile squamous cell carcinoma (SCC). Patients...